Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2013-09-30 Regulatory Filings
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
REGISTRATION STATEMENT
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, as indicated by the header and the text referencing the Securities Act of 1933. It includes detailed information about the securities being registered, the offering, the company's business overview, risk factors, management discussion and analysis, and financial statements. This type of filing is used for initial public offerings or other securities registrations and is not an annual report, earnings release, or any other report type listed. The S-1 is a registration statement, which is a regulatory filing but does not fit into the other specific categories such as Annual Report (10-K), Earnings Release, or Capital/Financing Update. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2013-09-30 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 25, 2013. It reports a merger transaction where Actinium Corporation was merged into Actinium Pharmaceuticals, Inc. The document details the exchange of shares and the acquisition of all outstanding equity securities of Actinium Corporation. It also mentions the private transaction exemption under securities laws. The content is a regulatory announcement of a corporate event (merger) rather than a full merger proxy statement or detailed merger filing. The document length is 3464 characters, which is relatively short and consistent with a current report. Therefore, the filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing a merger event but does not contain the detailed merger or tender offer filings (which would be MA or TAR).
2013-09-30 English
WITHDAWAL REQUEST
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the SEC requesting withdrawal of a Registration Statement on Form S-1 under Rule 477. It discusses the withdrawal of a registration statement related to a share exchange and does not contain financial statements or report data. The document is short (2476 characters) and is clearly an announcement/request related to regulatory filings rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and request to the SEC.
2013-09-30 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 16, 2013. The content focuses on the resignation of an interim CEO and the appointment of a new CEO, including detailed background information, terms of employment, compensation, and agreements related to the new CEO. There are no financial statements or performance data included. The primary subject is changes in senior management and board appointments. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is sufficient and contains detailed management change information, not just a brief announcement or certification, so it is not Regulatory Filings (RNS). Therefore, the correct classification is MANG with high confidence.
2013-09-20 English
Regulatory Filings 2013
Regulatory Filings
2013-09-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2013-09-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.